四川省细胞生物学会第十一届理事，四川省细胞生物学会细胞代谢专委会副主任委员，担任Journal of Controlled Release，Acta biomaterialia，Molecular Pharmaceutics等杂志特邀审稿人，国家自然科学基金同行评议专家。

主要研究课题：

1、国家自然科学基金面上项目，82370869，主持；

2、国家自然科学基金面上项目，82170874，主持；

3、国家自然科学基金面上项目，81870599，主持；

4、国家自然科学基金青年基金，81603035，主持；

5、四川省科技厅青年基金，2023NSFSC1541，主持

6、四川省科技厅重点研发项目，2020YFS0064，主持；

7、中国博士后科学基金特别资助，2018T110986，主持；

8、中国博士后科学基金面上资助，2017M612981，主持；

9、国家自然科学基金重点项目，81930020，主研；

10、四川省科技厅青年创新团队，2023NSFSC1993，主研。

代表论著（仅列近5年15篇）：

1. Zhang J, Huang Y, Li H, Xu P, Liu Q, Sun Y, Zhang Z, Wu T, Tang Q, Jia Q, Xia Y, Xu Y, Jing X, Li J, Mo L, Xie W, Qu A, He J^*, Li Y^*. B3galt5 functions as a PXR target gene and regulates obesity and insulin resistance by maintaining intestinal integrity. Nat Commun. 2024, 15(1):5919. (IF=14.7)

2. Zhang J, Zhang T, Zhang Z, Jia Q, Chen J, Li J, Song H, Li J, Xiong Y, Mo L, He J^*, Li Y^*. The dual-target nanoparticles with ROS sensitivity inhibit the hedgehog signaling pathway and decrease oxidative stress in activated hepatic stellate cells to alleviate liver fibrosis, Adv Funct Mater, 2024, 2404658. (IF=18.5) 

3. Chen J, Zhang J, Xia Y, Li J, Jia Q, Zhang Z, Jing X, Xu Y, Zou L, Wang L, Song H, Li J, Liu Q, Xiong Y, Tang Q, Chen W, Yang N, Xu H, Li Y^*, He J^*. Reactive oxygen species-responsive delivery of a notch inhibitor to alleviate nonalcoholic steatohepatitis by inhibiting hepatic de novo lipogenesis and inflammation. Mol Pharm. 2024,21(6):2922-2936. (IF=4.5) 

4. Li Y, Zhang T, Zhang J, Liu Q, Jia Q, Chen W, Tang Q, Xiong Y, Xia Y, Xu Y, Mo L, Huang Y, He J^*. Dually fibronectin/CD44-mediated nanoparticles targeted disrupt the Golgi apparatus and inhibit the hedgehog signaling in activated hepatic stellate cells to alleviate liver fibrosis. Biomaterials. 2023, 301: 122232. (IF=14.0)

5. Xia Y, Xu Y, Liu Q, Zhang J, Zhang Z, Jia Q, Tang Q, Jing X, Li J, Chen J, Xiong Y, Li Y^*, He J^*. Glutaredoxin 1 regulates cholesterol metabolism and gallstone formation by influencing protein S-glutathionylation. Metabolism. 2023,145:155610. (IF=10.8)

6. Li R, Zhang J, Liu Q, Tang Q, Jia Q, Xiong Y, He J^*, Li Y^*. CREKA-modified liposomes target activated hepatic stellate cells to alleviate liver fibrosis by inhibiting collagen synthesis and angiogenesis. Acta Biomater. 2023,168:484-496. (IF=9.4)

7. Xu Y, Xia Y, Liu Q, Jing X, Tang Q, Zhang J, Jia Q, Zhang Z, Li J, Chen J, Xiong Y, Li Y^*, He J^*. Glutaredoxin-1 alleviates acetaminophen-induced liver injury by decreasing its toxic metabolites. J Pharm Anal. 2023,13(12):1548-1561. (IF=6.1)

8. Chen J, Liu Q, He J^*, Li Y^*. Immune responses in diabetic nephropathy: Pathogenic mechanisms and therapeutic target. Front Immunol. 2022,13:958790. (IF=5.7)

9. Zhang J^#, Li Y^#, Liu Q, Huang Y, Li R, Wu T, Zhang Z, Zhou J, Huang H, Tang Q, Huang C, Zhao Y, Zhang G, Jiang W, Mo L, Zhang J, Xie W, He J. Sirt6 Alleviated Liver Fibrosis by Deacetylating Conserved Lysine 54 on Smad2 in Hepatic Stellate Cells. Hepatology. 2021, 73(3):1140-1157. (共同一作，IF=12.9）

10. Huang C, Liu Q, Tang Q, Jing X, Wu T, Zhang J, Zhang G, Zhou J, Zhang Z, Zhao Y, Huang H, Xia Y, Yan J, Xiao J^*, Li Y^*, He J^*. Hepatocyte-specific deletion of Nlrp6 in mice exacerbates the development of non-alcoholic steatohepatitis. Free Radic Biol Med. 2021, 169:110-121. (IF=7.1)

11. Zhou J, Li R, Zhang JH, Liu QH, Wu T, Tang Q, Huang CY, Zhang ZJ, Huang Y, Huang H, Zhang GR, Zhao YN, Zhang T, Mo L, Li Y^*, He J^*. Targeting interstitial myofibroblast-expressed integrin alpha v beta 3 alleviates renal fibrosis. Mol Pharm. 2021, 18(3): 1373-1385. (IF=4.5)

12. Zhou J, Li R, Liu Q, Zhang J, Huang H, Huang C, Zhang G, Zhao Y, Wu T, Tang Q, Huang Y, Zhang Z, Li Y^*, He J^*. Blocking 5-LO pathway alleviates renal fibrosis by inhibiting the epithelial-mesenchymal transition. Biomed Pharmacother. 2021, 138:111470. (IF=6.9)

13. Li R^#, Li Y^#, Zhang J, Liu Q, Wu T, Zhou J, Huang H, Tang Q, Huang C, Huang Y, Zhang Z, Zhang G, Zhao Y, Ma L, Feng Y, Mo L, Han M, He J. Targeted delivery of celastrol to renal interstitial myofibroblasts using fibronectin-binding liposomes attenuates renal fibrosis and reduces systemic toxicity. J Control Release. 2020; 320:32-44. (共同一作，IF=10.5)

14. Zhang J, Li R, Liu Q, Zhou J, Huang H, Huang Y, Zhang Z, Wu T, Tang Q, Huang C, Zhao Y, Zhang G, Mo L, Li Y^*, He J^*. SB431542-loaded liposomes alleviate liver fibrosis by suppressing TGF-β signaling. Mol Pharm. 2020;17(11):4152-4162. (IF=4.5)

15. Li Y, Pu S, Liu Q, Li R, Zhang J, Wu T, Chen L, Li H, Yang X, Zou M, Xiao J, Xie W^*, He J^*. An integrin-based nanoparticle that targets activated hepatic stellate cells and alleviates liver fibrosis. J Control Release. 2019,303:77-90. (IF=10.5)

发明专利：

1、李艳萍，何金汗，张金行，莫莉，多肽在制备防治非酒精性脂肪性肝病的药物中的用途，中国，ZL202310249030.5； 

2、何金汗，李艳萍，吴桐，用于防治肥胖的中脑星形胶质细胞源性神经营养因子的融合蛋白，中国，ZL202010107989.1；

3、何金汗，李艳萍，莫莉，靶向棕色脂肪组织的递药系统，中国，ZL201810050344.1；

4、何金汗，李艳萍，马良，莫莉，SKLB023混合胶束及其制备方法和用途，中国，ZL201811391951.0。